loading
Gain Therapeutics Inc stock is traded at $1.63, with a volume of 86,159. It is down -2.41% in the last 24 hours and down -41.94% over the past month. Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
See More
Previous Close:
$1.66
Open:
$1.65
24h Volume:
86,159
Relative Volume:
0.23
Market Cap:
$43.15M
Revenue:
$210.70K
Net Income/Loss:
$-22.22M
P/E Ratio:
-0.8956
EPS:
-1.82
Net Cash Flow:
$-17.13M
1W Performance:
-7.16%
1M Performance:
-41.94%
6M Performance:
-35.20%
1Y Performance:
-21.74%
1-Day Range:
Value
$1.56
$1.6796
1-Week Range:
Value
$1.56
$2.00
52-Week Range:
Value
$0.89
$5.33

Gain Therapeutics Inc Stock (GANX) Company Profile

Name
Name
Gain Therapeutics Inc
Name
Phone
(301) 500-1556
Name
Address
4800 HAMPDEN LANE, BETHESDA
Name
Employee
32
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
GANX's Discussions on Twitter

Compare GANX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
GANX 1.64 43.15M 210.70K -22.22M -17.13M -1.82
VRTX 448.35 115.74B 10.63B -479.80M -1.35B 13.33
REGN 746.89 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.60 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.28 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.59 24.49B 3.30B -501.07M 1.03B 11.54

Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-12-21 Initiated BTIG Research Buy
Apr-12-21 Initiated Oppenheimer Outperform

Gain Therapeutics Inc Stock (GANX) Latest News

pulisher
Nov 19, 2024

Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn

Nov 19, 2024
pulisher
Nov 19, 2024

Stock market news: Renewable Japan jumps nearly 69% by mid-day, D. Western Therapeutics and Agile Media Network post strong gains - Business Upturn

Nov 19, 2024
pulisher
Nov 18, 2024

Gain Therapeutics Advances Parkinson’s Therapy Development - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn

Nov 18, 2024
pulisher
Nov 18, 2024

Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 15.1% in October - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Chesapeake Granite Wash Trust (OTCMKTS:CHKR) Sees Large Increase in Short Interest - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Tapestry (NYSE:TPR) Price Target Raised to $66.00 - Defense World

Nov 18, 2024
pulisher
Nov 16, 2024

Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Gain Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 16, 2024
pulisher
Nov 15, 2024

Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews

Nov 15, 2024
pulisher
Nov 15, 2024

Gain Therapeutics Inc (GANX) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Gain Therapeutics' Parkinson's Drug Shows 53% Activity Boost in Phase 1 Trial | GANX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

The Future Of Inflammation: The Inflammasome And Beyond - Citeline News & Insights

Nov 13, 2024
pulisher
Nov 12, 2024

Insiders of Tectonic Therapeutic, Inc. (NASDAQ:TECX) were rewarded after last week’s 10% gain - Simply Wall St

Nov 12, 2024
pulisher
Nov 07, 2024

Endeavour Silver Corp (EXK) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register

Nov 07, 2024
pulisher
Nov 07, 2024

Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St

Nov 07, 2024
pulisher
Nov 06, 2024

2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money

Nov 06, 2024
pulisher
Nov 05, 2024

CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga

Nov 05, 2024
pulisher
Nov 05, 2024

U.S. Stock market: Zoomcar Holdings (+192.21%), Avalon GloboCare (+56.73%), and Vimeo (+40.85%) experience significant gains during mid day trading - Business Upturn

Nov 05, 2024
pulisher
Nov 05, 2024

Canada Market top gains:Q2 Metals Corp rises 17.00% while Valeura Energy climbs 15.55% at midday - Business Upturn

Nov 05, 2024
pulisher
Nov 01, 2024

Hoping for a weight-loss pill? It could get closer to reality next week. - MarketWatch

Nov 01, 2024
pulisher
Nov 01, 2024

individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance

Nov 01, 2024
pulisher
Oct 31, 2024

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Yahoo Finance

Oct 31, 2024
pulisher
Oct 30, 2024

Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6% - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Oct 28, 2024
pulisher
Oct 28, 2024

Nuclear stocks gain on AI optimism: Oklo, NuScale, Centrus - Yahoo Finance

Oct 28, 2024
pulisher
Oct 24, 2024

Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance

Oct 24, 2024
pulisher
Oct 23, 2024

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St

Oct 23, 2024
pulisher
Oct 21, 2024

Gain Therapeutics Regains Nasdaq Compliance - Investing.com

Oct 21, 2024
pulisher
Oct 21, 2024

Gain Therapeutics Regains Nasdaq Compliance By Investing.com - Investing.com UK

Oct 21, 2024
pulisher
Oct 20, 2024

The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Oct 20, 2024
pulisher
Oct 18, 2024

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - MSN

Oct 18, 2024
pulisher
Oct 18, 2024

32 NMEs gain US FDA clearance through Q3, approvals up over 2023 - BioWorld Online

Oct 18, 2024
pulisher
Oct 16, 2024

Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN

Oct 16, 2024
pulisher
Oct 16, 2024

How should investors view Janux Therapeutics Inc (JANX)? - US Post News

Oct 16, 2024
pulisher
Oct 16, 2024

What was Gain Therapeutics Inc (GANX)’s performance in the last session? - US Post News

Oct 16, 2024
pulisher
Oct 15, 2024

Gain Therapeutics Inc [GANX] Investment Guide: What You Need to Know - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

GANX Stock: A Voyage Through Gain Therapeutics Inc’s Finances - The InvestChronicle

Oct 15, 2024
pulisher
Oct 15, 2024

Can you now get a good deal on Compass Therapeutics Inc’s shares? - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times

Oct 15, 2024
pulisher
Oct 14, 2024

Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Renaissance Technologies LLC Has $152,000 Stock Position in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Investing in Voyager Therapeutics (NASDAQ:VYGR) three years ago would have delivered you a 58% gain - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday - Benzinga

Oct 14, 2024
pulisher
Oct 10, 2024

Edgewise Therapeutics Inc (EWTX) Stock: Navigating Drops and Gains - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

Seres Therapeutics gains amid takeover speculation - Seeking Alpha

Oct 10, 2024

Gain Therapeutics Inc Stock (GANX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):